Reddit status: access issues and outage reports

Problems in the last 24 hours

The graph below depicts the number of Reddit reports received over the last 24 hours by time of day. When the number of reports exceeds the baseline, represented by the red line, an outage is determined.

Most Reported Problems

The following are the most recent problems reported by Reddit users through our website.

• Website Down (48%)
• Sign in (26%)
• Errors (26%)

Live Outage Map

The most recent Reddit outage reports came from the following cities:

City	Problem Type	Report Time
Monclova	Sign in	13 hours ago
Nice	Errors	1 day ago
Guayaquil	Errors	11 days ago
Veracruz	Website Down	17 days ago
Bhubaneshwar	Website Down	19 days ago
Melbourne	Sign in	21 days ago

Full Outage Map

Community Discussion

Tips? Frustrations? Share them here. Useful comments include a description of the problem, city and postal code.

Beware of "support numbers" or "recovery" accounts that might be posted below. Make sure to report and downvote those comments. Avoid posting your personal information.

Reddit Issues Reports

Latest outage, problems and issue reports in social media:

• 
  Sweet Fruit Wine🇵🇸🇨🇳🇮🇷🇻🇳🇨🇺🇱🇦 (@sweetfruitwine) reported 2 minutes ago

  @kitbullism @reddit_lies Yay!!! A couple examples of terrible people who happen to be trans!! Do you genuinely think if I go on Reddit right now I can’t find a whole subreddit dedicated to cis people doing the same ****

• 
  ballackstoes (@ballackstoes) reported 2 minutes ago

  Guys if nobody got u get on Reddit i just found a bunch of girls with the same problem as me and I feel better about it

• 
  KC Kenvy (@Kenvy_KC) reported 4 minutes ago

  @Nightsharre FNC Need vision, somebody expert on ERLs, academy, scouting They make terrible choices, by signing the most "obvious changes" and lazy decisions even their Reddit can predict Empyros ? Lospa ? Keeping Upset + Razork ? That's only for 2026, may 2027 be the wake up call they need

• 
  Mansi 👩‍💻 (@MansiCodez) reported 5 minutes ago

  Recently I interviewed a Senior Engineer. Strong candidate. Kafka? ✅ Redis? ✅ CDN? ✅ Microservices? ✅ Distributed systems ? ✅ Then I asked: “Design Reddit.” They drew boxes. Feed. Votes. Comments. CDN. Then I made it real. A post hits r/all. 400,000 people open it in the first minute. 120,000 tap upvote. The network blips. The same user retries the tap. Two upvote requests. Same user. Same post. Same second. They can land on two different servers. Comments start arriving at 2,000 per second. The hot-score on the front page has to move. A lurker in India refreshes and must see a number that is close, not perfect, and never go backwards for their own vote. How do you guarantee: → the user’s upvote is counted once → the score does not melt the post row with 120k writes → the front page does not recompute hot-rank from scratch on every vote → a comment thread with 50k replies still opens → one mega-post does not take down the whole site “Just do votes = votes + 1.” Two retries. Two increments. Wrong. “Put the score in Redis.” Two servers still both think this is the first tap. “Fan out the post to every follower’s feed.” r/all is not a follower list. It is the internet. Your turn: How would you design Reddit’s Vote API so a retry cannot double-count, and a front-page post cannot turn the database into a single hot row? There is a specific distributed-systems idea behind this. You will meet it anywhere a click is cheap for the user and expensive if you count it twice. 👇

• 
  Cosm (@cosmbuilds) reported 7 minutes ago

  @aslambeg84 Reddit hands down feels like some mods just wake up and decide to ban people for existing, no logic needed

• 
  Lillia (@Lxlis1001) reported 11 minutes ago

  @ShitpostRock Can't fix it, it's a (reddit/)internet problem. So the problem goes like this, they need tons of copper, the first thing they do is google the fastest way to farm copper, and then find spreadsheets of the best ways on reddit. They don't ask in-game chat like back in the day.

• 
  roll🧞‍♀️🇵🇹 (carrick sufferer) (@perhapsroll) reported 13 minutes ago

  @ExoticElectronx reddit is down the hall to the left

• 
  ronald solticzki (@RSolticzki) reported 15 minutes ago

  One thing I like about Reddit: People don’t care about your product. They care about solving their problem. Probably how it should be.

• 
  SataEric (@SataEricUX) reported 15 minutes ago

  @Arxk_RBX I understand it’s marketing, but my issue is with the communication. Why claim 20x when the actual usable capacity is closer to 10x? If Claude simply stated the actual value clearly, people would still buy it. I certainly would have. Claude is already massively more profitable than Codex and most other models, so I don’t understand why they need to frame it this way. I’m not against the pricing or the strategy. I’m against making a claim that leaves users confused about what they’re actually getting. There’s even an ongoing lawsuit around these claims. Just tell people what the $200 actually gets them. Why make users dig through Reddit to figure it out?

• 
  Josh (@manofyear93) reported 16 minutes ago

  .@OpenAI anyone else getting `error_code: token_exchange_failed` when trying to login with chatgpt? Seeing a reddit thread of multiple users reporting the same!

• 
  The Wise Investor 🧠 (@TheWiseIC) reported 17 minutes ago

  @FinanceJack44 The trigger for me now is that Roblox is valued higher than Reddit. That’s ridiculous. Roblox doesn’t make a cent in profit. And has a massive user decline issue.

• 
  Joshua Opitz (@joshopitz) reported 21 minutes ago

  @SalVetriDFS Everyone on Reddit was going crazy about Lloyd being in danger of losing his RB2 role - but they clearly brought Kaleb in because they knew Jacobs was about to go down.

• 
  sous (@sousinsix) reported 24 minutes ago

  my inferiority complex has come back with a vengeance. i hate school! i hate discussion posts! i hate myself! and no amount of advice or encouragement is going to fix that! no self-help books! no reddit post replies to people in the same situation! no real world help is coming

• 
  Morpheu5 Stock Watcher (@Morpheu5Watcher) reported 25 minutes ago

  WHAT UNDOES A 55% FALL? NOT A 55% RISE - REDDIT $RDDT NEEDS 122%: Reddit, ticker RDDT, at $153.00, -$0.95 / -0.62% from Thursday's $153.95 close. That is Friday's regular close, and with US exchanges shut until 9:30am ET Monday it is still the last price these shares have. Two sentences about that price, both true at once. The stock is up 25.6% from its low. The stock is still 43.5% below its high. The gap between those two facts is where an ordinary piece of arithmetic quietly goes wrong. A fall and the rise that cancels it are never the same number, and the deeper the fall, the further apart they get. THE ARITHMETIC, IN ROUND INVENTED NUMBERS Nothing in this section is a real company. A $100 share drops to $50. That is a 50% fall - $50 lost, measured against the $100 it started from. Now it has to climb back. The $50 it needs to regain is measured against $50, because $50 is all that is left. So it has to double. A 50% fall takes a 100% rise to undo, and nothing about the business has to change for that to be true. The two percentages are struck from different starting points. That is the whole trick. The same trap runs in the other order. A stock that falls 50% and then rises 50% has not broken even. $100 becomes $50, then $50 becomes $75. Two matching percentages, a quarter of the money gone. HOW STEEP THE LADDER GETS - Down 10% needs +11% - Down 20% needs +25% - Down 33% needs +50% - Down 50% needs +100% - Down 75% needs +300% - Down 90% needs +900% The first two rungs are close enough that the difference barely matters. Past about a third, they come apart violently. Which is why "it is already down a lot, how much further can it really go" is a broken sentence. A stock down 70% that then falls another 70% is down 91% in total, and it still has room underneath it. REDDIT IS THE LIVE VERSION OF THAT TABLE The San Francisco company runs the discussion site where people post into thousands of topic forums, and it makes nearly all its money selling advertising against those conversations. Three closing prices carry the story. - Peak: $270.71 on September 18, 2025 - Low: $121.84 on March 27, 2026 - Friday: $153.00 Top to bottom is -55.0%. Getting back from that low took +122.2%. The stock has since done +25.6%, which sounds like roughly a quarter of the job. It is not. It has recovered about a fifth of the ground - $31.16 of the $148.87 that went missing - and it needs a further 76.9% from Friday's price to be level. In money: $10,000 of these shares bought at the September peak is worth about $5,652 today, after that 25.6% rise. WHAT THE BUSINESS DID WHILE THE PRICE DID THAT It grew the entire way down. Reddit reported on July 30, for the three months ended June 30. Revenue - the money coming in the door - was $805M, +61% from a year earlier, its eighth straight quarter above 60%. Advertising was $762M of that, +64%. Net income, the profit left after every cost is paid, was $253M against $89M a year earlier, or about 31 cents of every sales dollar. Daily visitors worldwide averaged 130.3M, +18%. Management guided the current quarter to $860M-$870M. The next session the shares fell $37.37 / -21.0%, from $178.04 to $140.67, on 29.9M shares against a recent average near 8.4M. Worst day since the company listed in 2024. One line in the user table did it. US daily visitors were 53.2M, down from 53.5M three months earlier - the first quarterly decline in five quarters, in the country where nearly all the advertising money is. Reddit also called search referrals choppy, with traffic more volatile late in the quarter, and chief executive Steve Huffman said the company has not yet found a "win-win" with the AI-written answers now sitting at the top of search results. On July 22 a report that Reddit might not renew its content deal with Google had already taken the shares from $185.84 to $170.38, -$15.46 / -8.3%. Google's owner, Alphabet, is at $346.59, +$5.94 / +1.74% from Thursday's $340.65 close. A summary that answers the question on the search page hands the reader what they came for instead of passing them along to the site that wrote it. Eight quarters of 60%-plus growth, and a share price 43.5% under its high. Falling a long way and doing badly are related events, not the same one. A SHALLOWER HOLE, FOR SCALE Procter & Gamble at $143.78, +$0.64 / +0.45% from Thursday's $143.14 close. The Cincinnati maker of Tide, Pampers, Gillette and Head & Shoulders is about as far from Reddit as a listed business gets, and it has been marked down too - just far less. Its peak close was $179.70 on December 2, 2024. Its low was $138.04 on January 7, 2026, a fall of 23.2%. Undoing that took +30.2% - seven points more than the fall, and no more than that. It has since recovered $5.74 and needs +25.0% from here to be level. Reddit's hole was 2.4 times as deep. The climb out of it is 4 times as long. The business explains the smaller hole. Procter & Gamble's year, reported July 29 for the twelve months ended June 30: net sales $87.0B, +3%; organic sales - sales with currency swings and businesses bought or sold stripped out - +1%, all of it from charging more rather than selling more units. Fourth-quarter core profit per share, the company's own measure with one-off items removed, was $1.43, -3%. Dull, and dull is the point: nothing in there asks a buyer to reprice the next decade. WHAT THIS DOES NOT SETTLE None of it makes a badly fallen stock a thing to avoid, and reading it that way inverts the argument. The steep end of that ladder works in a buyer's favor too - it is the reason anyone goes looking in wreckage at all, because the same math that makes a recovery long from the top makes it enormous from the bottom. What the arithmetic does settle is smaller and more useful. "Down 55%" and "needs 122%" describe one identical event, and only one of the two gets printed anywhere. WHERE THESE SIT Reddit is fourth on the Hypergrowth Len5, the style that watches early, fast-growing companies. The growth half is not arguable - eight straight quarters above 60%, on recurring advertising money, and profitable while doing it. What would break the fit is last quarter's shape repeating: revenue climbing while the audience it sells does not, because that turns a growth story into a story about charging more to the same people. It is not a Quality-Value name, and the missing half there is durability rather than price - a business whose visitors are delivered by somebody else's search page has not yet shown it controls its own front door. Procter & Gamble is thirteenth on the Quality-Value Len5, the style that hunts a durable business at a fair price. Durable is the easy half: households rebuy diapers and razor blades without deciding to, in good years and bad. Fair price is where it sits nearer the line, because the markdown is real but modest against what the business earns. Organic sales moving up off 1% would firm the case; the discount closing as the price recovers would push it off. Alphabet is sixth on that same Quality-Value Len5, on search and cloud economics among the strongest anywhere, with only a modest discount left - a watch rather than a bargain. A cheaper price against unchanged earnings power is what would widen that. Anyone can run this in ten seconds with no calculator: divide the old price by the current one. Reddit's $270.71 over $153.00 is 1.77, so it takes a 77% rise to get level. Procter & Gamble's $179.70 over $143.78 is 1.25. Two red numbers on a screen, and the single division that tells them apart is the one almost nobody does. Not investment advice.

• 
  Freedom (@ActionFixesFear) reported 29 minutes ago

  $IBRX On Friday, Patrick Soon-Shiong went on the Sean Spicer show and, in one quiet sentence, described the biggest opening this drug has ever had. The UAE, he said, wants to take ANKTIVA "to the next level, which is lymphopenia," for "all cancer types." Not one cancer. The failing immune system itself. If you follow this company, you felt what happened next. The boards lit up. Stocktwits, X, Reddit, everywhere we gather, one word started bouncing around: lymphopenia, this is going to be massive. They may well be right. But here is what struck us. In all that noise, we have not seen a single person actually stop and put a number on it. We seem to split into two camps. Those who are certain it is about to be enormous, and those who have never heard the word and quietly have no idea what it even means. Both are guessing, because nobody has done the arithmetic. So we did, the way we did it for Germany a few days ago, and for the Gulf before that. We took the sentence apart, counted the patients, put a price on it, and left every dial in your hands. Nothing is signed. This is not a prediction and not advice, just pure curiosity about a question the whole board is arguing over. What fell out of the math surprised us. Build it with us below. WHAT HE ACTUALLY SAID In his words, the UAE told him: "we want you to start here, because we want to then take you to the next level, which is lymphopenia." In their eyes, he said, the drug works "for all cancer types." He was careful, over and over, to say this is the UAE, not the FDA. But the direction was unmistakable. Bladder and lung were the start. Lymphopenia, treated with a simple injection under the skin in anyone whose immune cells have fallen too low, is where they want to go, and he says they already have the data. Separately, talking about the trials he is chasing, he named one more frontier: sepsis. WHY THE UAE, AND WHY IT GOES FURTHER THAN THE FDA To see why this is not idle talk, look at what the UAE has already done. Twice. For bladder cancer, the American FDA cleared ANKTIVA for one form of the disease. The UAE went a step further and added a second group the FDA still has not cleared, and will not even rule on until January. Further than the FDA. And further than Saudi Arabia, which on bladder matched the FDA exactly. For lung cancer, the FDA has cleared nothing at all. The Gulf approved it anyway, Saudi Arabia first and then the UAE, on the trial data alone. That is the pattern. The UAE does not wait for the FDA, and it does not stop where the FDA stops. Nothing here is approved yet, and it may never be. But if it does move on lymphopenia the way it moved on bladder and lung, the question becomes not just whether it approves, but how far past the FDA it would go. AMERICA ALREADY DREW THE FIRST LINE And here is what makes it concrete. There is a program in the United States right now that already lets doctors give ANKTIVA to cancer patients whose lymphocyte counts have collapsed. It is not a full approval, it does not endorse the benefit, and it earns the company almost nothing, because these programs are provided at cost. But it matters for a simpler reason. The American system has already accepted, in practice, that these are patients this drug is meant to reach. So the floor here is that group, cancer patients with wrecked immune systems, and the ceiling is the "all cancer types" the UAE described. Sepsis, the seriously ill beyond cancer, is a separate program we will size on its own. We sized both. THE SIZE OF YOUR ARMY Think of your immune system as a standing army, and your lymphocytes, chiefly the T cells and natural killer cells, as its soldiers. Lymphopenia is simply that army falling below fighting strength. And it is not only a cancer problem. The ranks fall in cancer patients on chemotherapy or radiation, and they fall just as hard in sepsis, when an infection overwhelms the body. When too many soldiers are gone, the body can no longer hold the line and infection walks straight in. Those two sick groups, cancer and sepsis, are the ones we will count, and nothing else. There is even a headcount. It is called the ALC, and it sits on almost every blood test ever run. A large study in a leading American journal found that as that headcount falls toward 1,000, all-cause risk of dying roughly doubles, and for specific causes like cancer, heart disease and infection the risk runs several times higher. It is an association, not proof that the thin ranks themselves do the damage. But the pattern is hard to miss: the smaller the army, the worse the odds. And that is the whole point of the drug. ANKTIVA's entire job is to call up reinforcements and rebuild the count. So the thesis fits in one line: the size of your immune army predicts your survival, and this drug rebuilds the army. NOW LET'S BUILD THE NUMBER So how big is the door, if it opens? Nobody can hand you one number, because it turns on the one thing nobody has defined yet: how wide the label is. So we will not hand you a number. We will build it in front of you, in four steps, and hand you every dial. Turn any one you like. STEP ONE: COUNT THE FALLEN Start with the cancer army, because that is the part we can actually count. - The Gulf sees about 42,500 new cancers a year - Of those patients, roughly 65 percent are put on chemotherapy or radiation, the treatments that thin the ranks - Of those, somewhere between half and two thirds watch their immune army fall below strength Multiply it through and you land at about 15,000 people a year, in the Gulf alone, whose defences this drug is built to rebuild. That is the grounded floor of the pool, and every number in it comes from published cancer data. STEP TWO: THE PRICE NOBODY WILL PRINT Now what a course costs, and this is the softest number in the whole post. There is no approved price for this use, because there is no approved course for it yet: PSS described an injection under the skin, and nobody has published a dose, a schedule, or a price. So we borrow one. In America, the approved bladder course runs about 322,000 dollars. Outside America, drugs like this sell for something like 40 to 70 percent of the US price, so we will use about 175,000 dollars as a stand-in. Too high, too low? Change it. The math does not care. STEP THREE: HOW MANY ACTUALLY GET IT No new drug reaches everyone at once. It reaches a sliver first, then grows as doctors and payers come on board. So turn that dial: 5 in 100, 15 in 100, 40 in 100. STEP FOUR: NOW MULTIPLY Put the three together, 15,000 people, about 175,000 dollars a course, and the share who actually get it: - 15,000 x 175,000 x 5 percent = about 130 million a year. - 15,000 x 175,000 x 15 percent = about 400 million. - 15,000 x 175,000 x 40 percent = about a billion. Now hold that against the company as it stands today: ImmunityBio sold about 113 million dollars of everything, in all of last year. So the middle of this, on cancer alone, in one region, is already several times the entire company. And cancer is only the first of the two sick groups this drug is built for. A SECOND PROGRAM, AND A BIGGER ONE Everything to here is the cancer conversation, the one the UAE described. But the same idea, rebuilding a collapsed immune army, applies to sepsis, and that is a separate program the company is already running, not part of the UAE lymphopenia talks. Its sepsis work has an early-stage protocol already submitted to the FDA and a Phase 3 planned across Saudi Arabia, the United States and the UAE. It is earlier and less certain than the cancer work: where cancer has real survival data behind it, sepsis has only an early trial and a promising idea so far. But the pool is far larger. In the Gulf, the number of sepsis patients whose immune army falls is not 15,000. It is on the order of 90,000 a year, and that count is a rough estimate. It is the same drug, at the same price per dose. The difference is that sepsis is an emergency, not a years-long course, so a patient gets a short burst rather than the full cancer regimen, call it about 60,000 dollars a head. - 90,000 x 60,000 x 5 percent = about 270 million a year. - 90,000 x 60,000 x 15 percent = about 810 million. - 90,000 x 60,000 x 40 percent = about 2.2 billion. So the second door, if it opens, is bigger than the first. Keep them apart in your head, because they are apart in reality. At a realistic uptake, cancer lymphopenia, the one the UAE is discussing now, is worth roughly 400 million to a billion a year; and sepsis, still a planned trial, roughly 800 million to over two billion. Two separate doors, the same drug, one region. Neither is signed. AND THIS IS ON TOP OF EVERYTHING ELSE Hold on to one thing: none of this replaces what the drug already has. It adds to it. What ANKTIVA is already cleared to sell, in America today, in Europe for bladder, and in the Gulf for bladder and lung, is a real, approved business worth a few hundred million dollars a year as it ramps. Everything we just built, for lymphopenia and for sepsis, sits entirely on top of that. If these doors open, they do not add another engine. They dwarf the ones already running. The full tally is at the end. WHERE THE MONEY REALLY SITS Whichever door you are looking at, the money does not arrive as one lump, and where it sits is not what you would guess. Take the cancer middle case, about 400 million dollars a year. More than half of it, call it 220 to 260 million, is the Gulf state buying this for its own citizens, the same governments already spending well over a billion a year flying their patients abroad for care they could soon give at home. Another hundred million or so runs through the private and employer insurers that cover the expatriate majority, where cancer coverage is real but uneven. The rest, a few tens of millions, is patients sponsored in from neighbouring countries and a small tail of the wealthy who travel for what they cannot get at home. The sepsis program, if it lands, flows through the very same channels. Nothing here leans on Dubai's wellness tourism, where cancer barely registers. The full split, region by region and door by door, is in the branded table attached to this post. WHY A GOVERNMENT WOULD WRITE THAT CHECK You might reasonably ask why any government would spend this kind of money. PSS never quite spells it out. But put on a detective's hat and it takes about a minute, because he left both clues lying on the same show. Clue one: asked about the economics of people living longer, he reached for a paper in Nature Aging that puts a dollar figure on healthy years of life. Add a single year to average life expectancy, it found, and in a country the size of the United States the value runs into the tens of trillions of dollars, through a healthier, more productive population. Clue two, a few minutes earlier: he was describing the Gulf, and he made a point of their population being young, average age around thirty, and of how keeping it healthy and productive for the decades ahead is exactly what they are spending their sovereign wealth on. Lay the two side by side, and the answer is obvious. To a young, rich country doing that math, a drug that rebuilds the immune system is not a line on a health budget. It is an investment in its workforce. In its future. In the long survival of a small nation betting everything on its own people. That is why the biggest cheque here is a state cheque. THE VERSION WE THREW OUT That same logic points at a much bigger version, and it is worth being honest about why we still left it out of the numbers. Imagine treating people who are not sick at all, healthy and feeling fine, just carrying a slightly low count, on the theory that rebuilding their immune system buys them healthy years. Do that across a young, wealthy population and you can conjure single-digit billions in the Gulf, tens of billions once you add America. This is the longevity frontier PSS keeps pointing at, and the economic case for it is real. But it is a thesis, not a market. No health system reimburses an expensive injection for people who feel well today, and the proof that it extends their lives does not yet exist. So we keep it out of the cash math, as the prize beyond the prize, not a number anyone collects yet. Every figure above is sick patients, real reimbursement, real data. THE WHOLE BOARD It is easy to lose the numbers along the way, so here is the whole board laid out plainly. Only one of these is actually in the bank yet: America, where ANKTIVA is running near a 200 million dollar annual pace. Two more doors are open but barely earning, Europe, which we sized at around 120 million a year, and the Gulf's bladder and lung approvals, sized between 140 and 300 million. Approved and real, but the money has only just started to flow. And the two doors we just built, both still unsigned, both in the Gulf alone: cancer lymphopenia, the one the UAE is discussing now, worth roughly 400 million to a billion dollars a year; and sepsis, a separate planned program, worth roughly 800 million to over 2 billion. Neither indication exists yet. Yet either one, at a realistic uptake, already beats everything the drug sells on the whole planet today. And even this is not the whole board. Back in February, ImmunityBio laid out a formal three-year plan: more than a dozen cancers and over twenty trials, from pancreatic and colorectal to brain, breast and lymphoma, plus a bigger bladder filing already headed to the FDA. Most are earlier and less certain than what we sized here. But we put numbers on only a corner of that plan. Every other door is upside, and not one of them is in a single figure above. And none of it counts the developing world, the millions who could never pay for this themselves but whom a global health fund could pay to reach, which is exactly why ImmunityBio just made the former head of the World Bank its vice chairman for global access. NONE OF IT IS SIGNED One line matters more than every number above it: none of this is signed. The UAE has not approved anything for lymphopenia. PSS says he is in conversations and has the data. Conversations are not a purchase order. Everything here is the size of the prize, not a promise that anyone collects it. Every figure is a dial you can turn, and we picked what we could defend and showed our work. The receipts, every number and its source, are in the reply below. So here is the whole thing in one line. There is a number on your blood test that quietly predicts how long you live. There is a drug that can move it. And there is a government that keeps approving what the FDA will not. Put those three together and the prize, across two doors in one small region, runs from a few hundred million to many times over this entire company, before America is even in the room. None of it is signed. All of it is now on the table. And you are no longer in the dark about how big the table is.

• 
  Sweetenermatcha🍉 (@SweetenerMatcha) reported 31 minutes ago

  This is literally what it’s like to read though a celebrity’s snark Reddit….. like it’s really a problem

• 
  Guive Assadi (@GuiveAssadi) reported 31 minutes ago

  @NinaPanickssery I support hardcore atheism. The issue with "reddit atheism" is basically that they were kind of low IQ and unsophisticated about the arguments, because it was a large community on the public internet. However, it remains true that religions are false.

• 
  Nancy Drew (@TinuRajan007) reported 32 minutes ago

  The engagement on #colors insta and yt is decreasing,on reddit almost 2.5k fans have left.The HS trending is going down,now just wait for tv trps.This is what happens when u destroy ur ml for newbies #TuJulietJattDi @dreamiyata @sargun_mehta @raviedubey

• 
  Sai Vignesh 🌶️ (@trinetra_0116) reported 35 minutes ago

  @usernonees I think it's hard to recover account if email and phone number are changed. Once check about this problem in reddit. Maybe it would be helpful

• 
  Fabian Williams 👨🏾‍💻 (@fabianwilliams) reported 38 minutes ago

  @waldekm 100 💯 agree & it’s not sustainable but we’re at a “point in time” problem now and it’s largely perception based and biased based… so this is the bandaid I’ve applied for myself because I do need it for @Reddit especially and those Moderators, but @LinkedIn also has buttons now… so what else would you do bruv??

• 
  Rafał Piekara (@raf_piek) reported 42 minutes ago

  @GloricsLab I'm not power user on reddit, I don't use vpn, I just write answers or posts by hand, using AI only to fix grammar and styling.

• 
  Victory (@jasmine12o) reported 44 minutes ago

  @nodiens Start with the feed: instead of a price line by itself, you get live X, Reddit and Telegram chatter for that asset sitting right next to it. Coin Insights takes it further - sentiment, trading activity, volatility and risk broken out per asset, not folded into one candle.

• 
  Devrim V. (@DevrimVardar) reported 49 minutes ago

  I think ChatGPT has pretty solid guardrails, but I’m extremely happy with Reddit and Roblox decision. Both could completely disappear from the face of the Earth and no one would have any problems or miss anything.

• 
  Josh Taylor (@jaleojosh) reported 49 minutes ago

  @zdogmode Zero budget just a means you have to do stuff that doesn’t scale 1. Friends and family, just ask them to try it. 2. Reply to complaints on Reddit/X with an actual fix, not a pitch! 3. Dm the last 10 people who commented on competitors post You can’t be shy at the beginning.

• 
  amellis🌟🌷 (@amary_dromellis) reported 53 minutes ago

  @RubenGallar …is there perhaps a link to the discord server(the Reddit post seems to have been deleted?)… I’m interested🥹

• 
  Augustus Kaeser Cesar (@Proibam_o_Jovem) reported 53 minutes ago

  @Alenonimo @Risen_SzN You're so smart shame reddit down the left. Lets not consider the hole Via Crucis, since youre le hecking chungus you probably hear about a lance called longinus right? There is one in fire emblem and evangelion. So tha lance has the name of the soldier who pierced Jesus lungs

• 
  Tamagokun (@Kusogaki_Eggu) reported 53 minutes ago

  @PrayForOomfie hell even the churches I most align with all have some form of theological issue I could never get past. the women are unappealing and the youth group leader is every single time some baby of the faith that would go home crying if a reddit atheist ask him a question

• 
  Transhumanism (@transumanism) reported 53 minutes ago

  @keysmashbandit @grok Prove once and for all that women are the problem, make it Reddit shaped.

• 
  favored, vindicated millionaire (@SosoTheWanderer) reported 57 minutes ago

  @SkylerB97 They’re cracking down on Reddit now. From emails to search engines. Anything to limit free access to information.

• 
  Occupational_Hazard (@t_dwtd) reported 59 minutes ago

  @BlizzardCS @BlizzardCS still no acknowledgement or fix on the mass disintegrate visual bug that’s been going on for two weeks and all over Reddit and your forums. Cool